Predictive Tool Developed by Roswell Park-OmniSeq Team Accurately Reflects Response to Checkpoint Inhibition
Algorithm highlighted during ASCO Annual Meeting accurately predicted Anti-PD-L1 response in 90% of cases
Article ID: 675971
Released: 6-Jun-2017 12:05 PM EDT
Source Newsroom: Roswell Park Cancer Institute
Newswise — BUFFALO, N.Y. — The class of immunotherapies known as checkpoint inhibitors have proven to be a highly effective and advantageous treatment option for many cancer patients, but they don’t work well for everyone, and oncologists have no reliable way to determine in advance which patients are likely to respond to these drugs. Looking to identify a genetic profile to predict how patients will respond to checkpoint inhibition, also known as anti PD-L1 therapy, researchers from Roswell Park Cancer Institute and OmniSeq collaborated to sequence the tumors of patients who had completed treatment with checkpoint inhibitors. They reported the results of this analysis at the American Society of Clinical Oncology (ASCO) 53rd Annual Meeting in Chicago.
“While some patients will respond well to checkpoint inhibitors, many will see their tumors progress quickly, so giving them these treatments actually could hurt more than it helps. The task of developing a predictive tool to help oncologists determine which patients will and will not respond to anti-PD-L1 therapy is a matter of high priority,” says Carl Morrison, MD, DVM, Executive Director of the Center for Personalized Medicine at Roswell Park and founder and Chief Scientific Officer of OmniSeq.
The research team discovered a set of 54 immune-related genes using expression data from whole transcriptome RNA-sequencing in 300 tumor specimens. They then designed a sequencing test to measure both gene expression and tumor mutational burden from a population of 167 Roswell Park patients previously treated with approved checkpoint inhibitors, with complete treatment and response data available for 87 patients. From these measurements and data, the team created and tested an algorithm designed to predict clinical response to checkpoint inhibition. Their algorithm, which incorporated expression data for those 54 genes along with a patient’s mutational burden, accurately reflected therapeutic response for 90% of patients. By comparison, an analysis based on positive PD-L1 immunohistochemistry results or high mutational burden status alone correctly predicted response in only 30% of cases.
“Our results show that this two-pronged algorithm — expression analysis for the 54-gene signature we identified, on top of mutational burden — may prove to be a highly accurate tool for predicting treatment response,” notes Dr. Morrison. “We’re excited by these striking findings and look forward to validating our results in a larger study.”
The poster, “Algorithmic prediction of response to checkpoint inhibitors,” is ASCO 2017 abstract 11565.
The poster was presented by Shipra Gandhi, a Clinical Fellow in the Department of Medicine at Roswell Park.
This release is also available in the Roswell Park online newsroom: https://www.roswellpark.org/media/news/predictive-tool-developed-roswell-park-omniseq-team-accurately-reflects-response
About Roswell Park: The mission of Roswell Park Cancer Institute (RPCI) is to understand, prevent and cure cancer. Founded in 1898, RPCI is one of the first cancer centers in the country to be named a National Cancer Institute-designated comprehensive cancer center and remains the only facility with this designation in Upstate New York. The Institute is a member of the prestigious National Comprehensive Cancer Network, an alliance of the nation’s leading cancer centers; maintains affiliate sites; and is a partner in national and international collaborative programs. For more information, visit www.roswellpark.org, call 1-877-ASK-RPCI (1-877-275-7724) or email email@example.com. Follow Roswell Park on Facebook and Twitter.
About OmniSeq LLC: OmniSeq, an innovation of Roswell Park Cancer Institute, is a molecular diagnostic laboratory based in Buffalo, New York. OmniSeq endeavors to find the right drug or the right trial for every patient by improving access to better cancer treatment options through molecular profiling. In addition to Immune Report Card, OmniSeq offers OmniSeq ComprehensiveSM, a 144 gene next generation sequencing assay that covers almost all known genetic alterations associated with an FDA-approved targeted therapy or genotype directed clinical trials. OmniSeq is proud to partner with pharmaceutical companies to provide research support for immuno-oncology development projects. For more information, call 1-800-781-1259 or visit www.omniseq.com.